Benchmark Lowers Cardio Diagnostics (NASDAQ:CDIO) Price Target to $1.35

Cardio Diagnostics (NASDAQ:CDIO) had its target price cut by Benchmark from $4.00 to $1.35 in a research note published on Friday morning, Benzinga reports. They currently have a speculative buy rating on the stock.

Cardio Diagnostics Price Performance

NASDAQ CDIO opened at $0.75 on Friday. Cardio Diagnostics has a 12-month low of $0.17 and a 12-month high of $3.56. The firm has a 50-day moving average price of $1.38 and a two-hundred day moving average price of $1.53.

Institutional Trading of Cardio Diagnostics

A hedge fund recently bought a new stake in Cardio Diagnostics stock. Vontobel Holding Ltd. bought a new stake in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 12,000 shares of the company’s stock, valued at approximately $30,000. Vontobel Holding Ltd. owned approximately 0.06% of Cardio Diagnostics at the end of the most recent quarter. 8.06% of the stock is owned by institutional investors and hedge funds.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc, an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.